Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells.

Kovacsovics-Bankowski M, Mauch K, Raber A, Streeter PR, Deans RJ, Maziarz RT, Van't Hof W.

Cytotherapy. 2008;10(7):730-42. doi: 10.1080/14653240802320245.

PMID:
18985479
2.

Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury.

Yasuhara T, Matsukawa N, Yu G, Xu L, Mays RW, Kovach J, Deans RJ, Hess DC, Carroll JE, Borlongan CV.

Cell Transplant. 2006;15(3):231-8.

PMID:
16719058
3.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

Maziarz RT, Devos T, Bachier CR, Goldstein SC, Leis JF, Devine SM, Meyers G, Gajewski JL, Maertens J, Deans RJ, Van't Hof W, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.

4.

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.

Camp DM, Loeffler DA, Farrah DM, Borneman JN, LeWitt PA.

J Neuroinflammation. 2009 Jun 5;6:17. doi: 10.1186/1742-2094-6-17.

5.

Adult bone marrow-derived stem cells for organ regeneration and repair.

Tögel F, Westenfelder C.

Dev Dyn. 2007 Dec;236(12):3321-31. Review.

6.

Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).

Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V, Schnitzbauer AA, Hutchinson J, Deans R, Ladenheim D, Graveen CA, Zeman F, Koller M, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH.

J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124.

7.

Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease.

Kovacsovics-Bankowski M, Streeter PR, Mauch KA, Frey MR, Raber A, van't Hof W, Deans R, Maziarz RT.

Cell Immunol. 2009;255(1-2):55-60. doi: 10.1016/j.cellimm.2008.10.004. Epub 2008 Nov 20.

PMID:
19022422
8.

Application of MultiStem(®) Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease.

Vaes B, Van't Hof W, Deans R, Pinxteren J.

Front Immunol. 2012 Nov 27;3:345. doi: 10.3389/fimmu.2012.00345. eCollection 2012.

9.

[Collection of hematopoietic progenitor cells from healthy donors].

Bojanić I, Cepulić BG, Mazić S.

Acta Med Croatica. 2009 Jun;63(3):237-44. Review. Croatian.

PMID:
19827352
10.

Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke.

Liao W, Xie J, Zhong J, Liu Y, Du L, Zhou B, Xu J, Liu P, Yang S, Wang J, Han Z, Han ZC.

Transplantation. 2009 Feb 15;87(3):350-9. doi: 10.1097/TP.0b013e318195742e.

PMID:
19202439
11.

Rat marrow-derived multipotent adult progenitor cells differentiate into skin epidermal cells in vivo.

Ji KH, Xiong J, Fan LX, Hu KM, Liu HQ.

J Dermatol. 2009 Jul;36(7):403-9. doi: 10.1111/j.1346-8138.2009.00666.x.

PMID:
19583688
12.

Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease.

Kakinuma S, Nakauchi H, Watanabe M.

J Gastroenterol. 2009;44(3):167-72. doi: 10.1007/s00535-008-2297-z. Epub 2009 Feb 13. Review.

PMID:
19214659
13.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
14.

Transplantation of dermal multipotent cells promotes survival and wound healing in rats with combined radiation and wound injury.

Shi C, Cheng T, Su Y, Mai Y, Qu J, Lou S, Ran X, Xu H, Luo C.

Radiat Res. 2004 Jul;162(1):56-63.

PMID:
15222801
16.

Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules.

Dressel R, Guan K, Nolte J, Elsner L, Monecke S, Nayernia K, Hasenfuss G, Engel W.

Biol Direct. 2009 Aug 28;4:31. doi: 10.1186/1745-6150-4-31.

17.

Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.

Auletta JJ, Cooke KR.

Curr Opin Pediatr. 2009 Feb;21(1):30-8. doi: 10.1097/MOP.0b013e3283207b2f. Review.

PMID:
19242239
18.

A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke.

Hess DC, Sila CA, Furlan AJ, Wechsler LR, Switzer JA, Mays RW.

Int J Stroke. 2014 Apr;9(3):381-6. doi: 10.1111/ijs.12065. Epub 2013 May 22.

PMID:
23692637
19.

Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.

Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C.

Transplantation. 2009 Jan 27;87(2):217-21. doi: 10.1097/TP.0b013e3181938998.

PMID:
19155975
20.

Immunomodulatory properties of human periodontal ligament stem cells.

Wada N, Menicanin D, Shi S, Bartold PM, Gronthos S.

J Cell Physiol. 2009 Jun;219(3):667-76. doi: 10.1002/jcp.21710.

PMID:
19160415
Items per page

Supplemental Content

Write to the Help Desk